Company news: Edelman aquires firm in Vietnam

Share this article:
PR firm Edelman announced Tuesday that it is increasing its reach to include Vietnam. The indie PR giant is poised to acquire AVC Communications, pending government approval. The new company will be called AVC Edelman and will report to Bob Grove, managing director of Edelman Southeast Asia. The PR firm said in a statement that Vietnam is a key location, having tripled its GDP over the last decade.  Edelman says it projects the country's GDP growth will hit 5% to 6% this year.

Wiley-Blackwell is adding 44 titles to its roster of publications. The company said in statement that 16 of the publications are new to the market, and 40 are being published in collaboration with other organizations. The acquisition will add eight titles to its open access program, which publishes primary research. The American Counseling Association, International Reading Association, and TESOL International Association are among the groups with journals that are part of this initiative.

The FDA said labels on statins will now advise patients and doctors that the drugs have been linked to memory loss, forgetfulness and confusion, along with an increased risk for type 2 diabetes. The FDA also says lovastatin may interact with other medications and increase the risk of muscle damage. The changes also include an omission: labels will no longer recommend routine liver enzyme monitoring. Americans bought over $26 billion of the top five drugs in the statin category for the year ended October 31, 2011, according to Wolters Kluwer Pharma Solutions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.